pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 15·1 min read
save

J&J reports 18,000 new prescriptions for Icotyde in first full quarter

Jul 15, 2026·read at Endpoints ↗Positive readoutPositive

Johnson & Johnson gave an update on the launch of its plaque-psoriasis drug Icotyde.

The company said that in its first full quarter on the market, Icotyde generated about 18,000 new prescriptions, showing early uptake.

J&J did not disclose revenue figures for the period, leaving the financial impact unclear.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “J&J touts Icotyde prescriptions, but not sales, in first full quarter”

read at Endpoints ↗
82 words · retrieved Jul 15
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
JOHNSON & JOHNSON2
drugs
ICOTYDE4icotrokinra hydrochloride4
topics
Psoriasis3

related stories

  • 6d agoJ&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absentBioSpace
  • Sep 286 immunology targets to sustain a mammoth I&I marketBioSpace
  • Sep 165 biotechs braving the commercial waters with product launchesBioSpace
  • Jul 14Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pillBioPharma Dive
  • 4d agoChutes & Ladders—Bausch + Lomb's returning CEO Saunders exits againFierce Biotech